A Bayesian Framework for Latent Compliance Modeling in Cluster Randomized Trials with One-Sided Noncompliance
summary
The gist
A Bayesian framework for latent compliance modeling in cluster randomized trials with one-sided noncompliance proposes a method to characterize how intervention effects vary across sources of…
In short
The paper proposes a Bayesian framework to analyze cluster randomized trials where implementation varies across clusters and individual compliance is binary. It uses a latent mixture model to capture heterogeneity in how interventions are implemented at the cluster level, linking these implementation types to individual compliance and outcomes. This allows for estimating intervention effects within specific implementation strata.
Key concepts
- Latent Implementation Strata
- This concept refers to unobserved groups of clusters defined by shared characteristics and observed implementation measures. The model uses a latent mixture model to summarize this heterogeneity, grouping clusters based on how they actually put the intervention into practice, rather than just their assigned treatment group.
- Joint Model
- A joint model is a statistical approach that simultaneously models multiple related variables—in this case, cluster-level implementation heterogeneity and individual compliance/outcomes. By linking these strata together, the framework can account for how the environment (implementation) influences both what individuals comply with and what their final outcomes are.
- CACEk
- CACEk stands for the complier average causal effect within a specific latent implementation stratum k. This measures the intervention's effect on individuals who complied, specifically within that particular implementation environment. It helps characterize how the treatment works differently depending on the cluster's underlying operational style.
- Pragmatic Cluster Randomized Trials (PCRCTs)
- These are clinical trials where healthcare providers are randomized, but both providers and patients might deviate from the assigned intervention. The framework is designed to handle this complexity by focusing on how implementation differences across clusters affect individual compliance and outcomes.
Terminology used across episodes
This episode discusses
- A Bayesian Framework for Latent Compliance Modeling in Cluster Randomized Trials with One-Sided Noncompliance · Paper Radio
The paper
A Bayesian Framework for Latent Compliance Modeling in Cluster Randomized Trials with One-Sided Noncompliance · Read on arXiv
Department of Biostatics, Brown University School of Public Health · Department of Health Services, Policy & Practice, Brown University School of Public Health
In pragmatic cluster randomized controlled trials (PCRCTs), healthcare providers are randomized, but intervention delivery and patient receipt may vary after assignment. In many PCRCTs, cluster-level implementation is measured using continuous implementation metrics, while individual compliance is recorded as a binary indicator. Standard complier average causal effect (CACE) estimands focus on individual-level compliance and do not account for heterogeneity in implementation across clusters. When intervention uptake is shaped by both cluster- and individual-level processes, it is of scientific interest to characterize how effects vary across these sources of compliance. We propose a Bayesian framework for PCRCTs with one-sided binary noncompliance at the individual level and one-sided partial compliance at the cluster level. The method uses a latent mixture model to summarize heterogeneity in cluster-level implementation based on baseline characteristics and treatment-arm implementation measures, and links these latent implementation strata to individual compliance and outcomes through a joint model. Because individual compliance and treatment-defined implementation measures are observed only under treatment assignment, the model imputes these quantities for control clusters and individuals assigned to control. The framework enables estimation of finite- and super-population intent-to-treat (ITT) and CACE estimands, both marginally and within latent implementation strata. We apply the method to the METRIcAL trial, a pragmatic cluster randomized study evaluating a personalized music intervention for nursing home residents with dementia. The analysis illustrates how accounting for implementation heterogeneity and individual compliance can provide insights beyond standard ITT analyses.
Transcript
Introduction to the show: ident: Statistics. The day in statistics: methods, theory and the inference under them.
Tom: We're looking at the paper: "A Bayesian Framework for Latent Compliance Modeling in Cluster Randomized Trials with One-Sided Noncompliance".
Paper summary: Tom: So we’re looking at this paper titled "A Bayesian Framework for Latent Compliance Modeling in Cluster Randomized Trials with One-Sided Noncompliance." Jane, what's the core idea they are pushing here?
Jane: Well, it tackles a problem where you have a cluster randomized controlled trial, or PCRCT, and you have both the healthcare providers and the patients potentially deviating from what they were supposed to do. The authors say that standard complier average causal effect estimands only look at how the individual patient complies, ignoring how different clusters actually implemented their intervention.
Tom: Right, so it’s about that heterogeneity in implementation across clusters, which is usually a big blind spot when we look at those standard CACE estimands. What exactly do they claim this framework does?
Jane: They propose using a latent mixture model to summarize that heterogeneity in cluster-level implementation based on baseline characteristics and observed metrics. Then, they link those latent implementation types directly to the individual compliance and the final outcomes through a joint model. This lets you estimate effects not just for the whole population, but also within different implementation types.
Lu: I like this because it moves beyond just looking at one type of noncompliance, like binary noncompliance. They are modeling partial compliance at the cluster level alongside binary compliance at the individual level, which is a step up from previous work that used a single measure for both > Page three of THIS PAPER — "We propose a Bayesian framework for analyzing PCRCTs with one-sided binary noncompliance at the individual level and one-sided partial compliance at the cluster level <ref:2509.15280#pg3,We propose a Bayesian framework for analyzing PCRCTs with one-sided binary>. The method uses a latent mixture model to summarize heterogeneity in cluster-level implementation based on pre-treatment characteristics and observed implementation measures, and links these latent implementation strata to individual compliance and outcomes through a joint model, there"
Meng: From my side, what I need to know is how this translates from theory to something we can actually deploy. If you have these latent strata, how does that affect the computational cost? Are we talking about something that runs smoothly on real traffic or is it just for theoretical exercises?
Paper summary: Lalam: Based on what I see in the structure of this paper, the framework is built to handle complexity by using a Dirichlet prior to regularize the estimation and reflect uncertainty in how many implementation strata exist > Page three of THIS PAPER — "The method uses a latent mixture model to summarize heterogeneity in cluster-level implementation based on pre-treatment characteristics and observed implementation measures, and links these latent implementation strata to individual compliance and outcomes through a joint model, there" <ref:2509.15280#pg3,The method uses a latent mixture model to summarize heterogeneity in cluster>
Tom: It sounds like they’re setting up a very detailed statistical structure. Jane, if we boil it down for someone just listening, what’s the big payoff here? Why does characterizing these different implementation patterns matter for the real world?
Jane: The payoff is being able to estimate intervention effects specifically among providers with similar implementation patterns and also among individuals who receive the intervention exactly as intended. It allows you to see how compliance behavior and outcome dependence are governed by that shared environment of how things get implemented > Page one of THIS PAPER — "In pragmatic cluster randomized controlled trials (PCRCTs), healthcare providers are randomized while both providers and patients may deviate from the assigned intervention <ref:2509.15280#pg1,In pragmatic cluster randomized controlled trials (PCRCTs), healthcare providers are randomized while>. In many PCRCTs, cluster-level implementation is measured using multiple continuous metrics, while individual compliance is recorded as a binary indicator"
Lu: It’s about moving beyond the naive view where you assume everyone in a cluster acts the same way. This framework treats the way an intervention gets put into practice—that implementation strategy—as a source of variation that directly influences what happens to patients > Page two of THIS PAPER — "Agitation and aggressive behaviors are common among cognitively impaired individuals residing in nursing homes (NHs) (Zuidema et al <ref:2509.15280#pg1>., two thousand seven) <ref:2509.15280#pg2>. These behaviors can decrease quality of life and accelerate cognitive decline (Garc´ıa-Alberca et al., two thousand nineteen; Shin et al <ref:2509.15280#pg2>., two thousand five), while also serving as a major source of stress for NH staff (Karlsen et al <ref:2509.15280#pg2,2005), while also serving as a major source of stress for NH>. two thousand twenty-three) and other residents (Rosen et al <ref:2509.15280#pg2,2023) and other residents (Rosen et al>. two thousand eight) <ref:2509.15280#pg2>. Antipsychotic and mood-stabilizing medications are commonly used to manage aggressive behaviors; however, these medications are associated with adverse events, including falls and increased mortality (Huybrechts et al. two thousand twelve) <ref:2509.15280#pg2>."
Meng: So you’re saying if we can identify that a specific cluster type—say, one with low targeting proportions—has a different outcome profile than another type, we can tailor the intervention strategy for those specific environments? That sounds like something I could actually use to deploy more efficiently.
Paper summary: Lalam: The authors show this by applying it to METRIcAL data and finding two distinct latent implementation strata based on facility size and targeting proportions > Appendix three Prior distributions for METRIcAL application — "Latent implementation strata are modeled as Si ∼ Categorical(π1, π2), (π1, π2) ∼ Diriclet(one one) Conditional on Si = k, the facility-level implementation measure (logit clinical proportion) and baseline facility characteristic follow Ci Zi Si = k ∼ MVN(µS k, Σ), k = one two"
Tom: Okay. So what’s the conclusion then? What is the ultimate value proposition of this whole "A Bayesian Framework for Latent Compliance Modeling in Cluster Randomized Trials with One-Sided Noncompliance"?
Jane: The framework itself is principled because it jointly models implementation heterogeneity and individual compliance > Page one of THIS PAPER — "We propose a Bayesian framework for PCRCTs with onesided binary noncompliance at the individual level and one-sided partial compliance at the cluster level <ref:2509.15280#pg1,We propose a Bayesian framework for PCRCTs with onesided binary noncompliance at>. The method uses a latent mixture model to summarize heterogeneity in cluster-level implementation based on pre-treatment characteristics and observed implementation measures, and links these latent implementation strata to individual compliance and outcomes through a joint model, there"
Tom: So it’s essentially giving us a more nuanced way to look at why an intervention might work differently depending on the context of its delivery. It moves us past just asking if the treatment worked overall.
Jane: Exactly. It enables estimation of effects among providers with similar implementation patterns and among individuals who receive the intervention as intended, which is something standard intent-to-treat analyses often miss > Page one of THIS PAPER — "The framework enables estimation of finite- and super-population intent-to-treat (ITT) and CACE estimands, both marginally and within latent implementation types" <ref:2509.15280#pg1>
Tom: That’s it. It gives us better causal estimates that are more specific to the context. We’ll be keeping an eye on how they handle those partial compliance assumptions in future work > Page three of THIS PAPER — "In many pragmatic trials, however, compliance may be partial rather than binary <ref:2509.15280#pg3,In many pragmatic trials, however, compliance may be partial rather than binary>. For example, individuals may receive different doses of an intervention (Jin and Rubin, two thousand eight), and clusters may vary in the intensity or scope of implementation" <ref:2509.15280#pg2>
Conclusion: Tom: So we've seen how they built this whole Bayesian framework for looking at cluster randomized trials when you have one-sided noncompliance, and now we need to talk about what it actually means for us as a way of thinking about these studies.
Jane: Exactly. The title is pretty long, right? "A Bayesian Framework for Latent Compliance Modeling in Cluster Randomized Trials with One-Sided Noncompliance." It sounds like a lot of math piled on top of a clinical problem, and we need to make sure we understand the core idea without getting lost in the notation.
Lu: The paper is essentially proposing a way to handle the mess when you measure implementation at the group level but compliance at the individual level, especially when people don't always follow through perfectly. They use this latent mixture model to sort those clusters into different types based on how they actually implemented things.
Meng: So, instead of just saying "this intervention worked for everyone," we can now say "this intervention worked differently depending on *how* the facility set it up." That’s a big difference when you’re trying to deploy something at scale.
Tom: Yeah, the implication is that we stop treating all clusters as one giant unit and start seeing the variation in delivery itself as a key driver of outcomes. It moves us from just looking at patient behavior to looking at system behavior.
Jane: It also lets researchers estimate effects for groups of providers who are similar in their implementation style, which is something standard intent-to-treat analyses completely miss. So we can get more specific causal effect estimates for those subgroups.
Lalam: I'm pretty confident in this direction because they show how the model handles the uncertainty and links that cluster heterogeneity directly to the individual outcomes, giving us super-population estimates that are much richer than what we usually get.
Tom: It gives us a principled way to analyze these kinds of pragmatic trials where both the setup and the execution are variable. We're seeing how this framework helps isolate what really drives change in patients when there's so much noise in how the treatment is actually delivered.
Jane: That leads perfectly into how they applied this to METRIcAL data, which showed that smaller facilities had different results than larger ones, giving us concrete examples of what these latent strata look like in practice.
More episodes
- Daily Summary for 2026-11-19
- 2310.07973-Statistical Performance Guarantee for Subgroup Identification with Generic Machine Learning
- 2408.09155-Learning Robust Treatment Rules for Censored Data
- Daily Summary for 2026-11-19
- 2603.23397-Kinetic Langevin Splitting Schemes for Constrained Sampling
- 2606.09906-An information-geometric framework for mapping maximum potential biodiversity
- 2603.27718-Induced replication and the assessment of models
- 1307.0898-Entropy of a Zipfian Distributed Lexicon
- 2406.19974-Generalizing self-normalized importance sampling with couplings
- 2412.10213-Collaborative Optimal Design of Controlled Experiments with Subject Covariates